Trial Profile
A Double Blind, Randomized, Placebo Controlled, Cross-over Study to Examine the Pharmacodynamic Effects of GSK1034702 on Neurophysiological Biomarkers of Cognition in Nicotine Abstained Otherwise Healthy Smokers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 03 Sep 2023
Price :
$35
*
At a glance
- Drugs GSK 1034702 (Primary)
- Indications Alzheimer's disease; Mild cognitive impairment
- Focus Biomarker; Pharmacodynamics
- Sponsors GlaxoSmithKline; GSK
- 20 Jul 2011 Results presented at the 2011 International Conference on Alzheimer's Disease.
- 16 Jun 2011 New trial record